Patents by Inventor Felix Jinhyun Kim

Felix Jinhyun Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230132717
    Abstract: The present disclosure relates, in certain embodiments, to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to disrupt virus lifecycle, infection, and/or dissemination. The compounds contemplated in the disclosure are useful in the prevention, treatment, and/or amelioration of virus infection, either alone or in combination with at least one additional therapeutic agent, which can be an antiviral agent and/or an agent that treats, ameliorates, and/or prevents one or more virus infection symptoms and/or co-morbidities. In certain embodiments, the Sigma receptor is a Sigma-1 receptor (also known as Sigma1) or Sigma-2 receptor (also known as Sigma2 or TMEM97). In certain embodiments, Sigma1 inhibitors/antagonists that cause and/or trigger ER stress and/or autophagy are useful within the methods of the disclosure.
    Type: Application
    Filed: March 30, 2021
    Publication date: May 4, 2023
    Inventors: Felix Jinhyun Kim, Holly Ramage
  • Publication number: 20230127965
    Abstract: The present disclosure relates, in certain embodiments, to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to disrupt virus lifecycle, infection, and/or dissemination. The compounds contemplated in the disclosure are useful in the treatment or amelioration of virus infection, such as but not limited to coronavirus infection, either alone or in combination with at least one additional therapeutic agent, which can be an antiviral agent and/or an agent that treats, ameliorates, and/or prevents one or more virus infection symptoms or co-morbidities. In certain embodiments, the Sigma receptor is a Sigma-1 receptor (also known as Sigma 1) or Sigma-2 receptor (also known as Sigma2 or TMEM97).
    Type: Application
    Filed: March 30, 2021
    Publication date: April 27, 2023
    Inventors: Felix Jinhyun Kim, Holly Ramage
  • Patent number: 8945583
    Abstract: The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: February 3, 2015
    Assignees: Centre National de la Recherche Scientifique, Universite de Montpellier 2
    Inventors: Jean-Luc Georges Laurent Battini, Nicolas Gabriel Albert Manel, Felix Jinhyun Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon
  • Publication number: 20100056448
    Abstract: The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.
    Type: Application
    Filed: August 26, 2009
    Publication date: March 4, 2010
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE MONTPELLIER II
    Inventors: Jean-Luc Georges Laurent BATTINI, Nicolas Gabriel Albert Manel, Felix Jinhyun Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon
  • Patent number: 7642061
    Abstract: The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: January 5, 2010
    Assignees: Centre National de la Recherche Scientifique, Universite Montpellier II
    Inventors: Jean-Luc Georges Laurent Battini, Nicolas Gabriel Albert Manel, Felix Jinhyun Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon
  • Publication number: 20090186338
    Abstract: The invention relates to the use of oligonucleotides from the nucleotide sequences coding for the amino-terminal region of the surface component (SU) of envelope proteins of PTLV viruses in order to perform methods of detecting every PTLV strain or PTLV-related viruses, e.g. for the detection of novel PTLV variants or viruses comprising sequences related to PTLV SUs. The invention also relates to primer pairs which are used to perform said detection methods and the novel PTLV variants thus detected.
    Type: Application
    Filed: February 10, 2009
    Publication date: July 23, 2009
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELIER II
    Inventors: FELIX Jinhyun KIM, NICOLAS GABRIEL ALBERT MANEL, KHAMOUS MARC MICHEL SITBON
  • Patent number: 7507529
    Abstract: The invention relates to the use of oligonucleotides from the nucleotide sequences coding for the amino-terminal region of the surface component (SU) of envelope proteins of PTLV viruses in order to perform methods of detecting every PTLV strain or PTLV-related viruses, e.g. for the detection of novel PTLV variants or viruses comprising sequences related to PTLV SUs. The invention also relates to primer pairs which are used to perform said detection methods and the novel PTLV variants thus detected.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: March 24, 2009
    Assignees: Centre National de la Recherche Scientifique, Universite de Montpellier II
    Inventors: Felix Jinhyun Kim, Nicolas Gabriel Albert Manel, Marc Khamous Michel Sitbon
  • Publication number: 20080268424
    Abstract: The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.
    Type: Application
    Filed: April 30, 2004
    Publication date: October 30, 2008
    Inventors: Jean-Luc Georges Laurent Battini, Nicolas Gabriel Albert Manel, Felix Jinhyun Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon